The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma.
P. D. Boasberg
Research Funding - Abraxis BioScience; Genentech
R. W. Weber
Research Funding - Abraxis BioScience; Genentech
S. Cruickshank
Research Funding - Abraxis BioScience; Genentech
O. Hamid
Research Funding - Abraxis BioScience
S. O'Day
Consultant or Advisory Role - Genentech (U); Roche (U)
Research Funding - Abraxis BioScience; Genentech
L. E. Spitler
Stock Ownership - Abraxis BioScience; Genentech